Neural precursor cell therapy - S Biomedics

Alternative Names: Embryonic stem cell derived neural precursor cells - S Biomedics; TED-N - S Biomedics

Latest Information Update: 27 May 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator S Biomedic
Class Neural stem cell therapies; Neuroprotectants; Pluripotent stem cell therapies; Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

23 Sep 2021 Phase-I/II clinical trials in Spinal cord injuries in South Korea (Intrathecal) (NCT04812431)
26 Mar 2021 S Biomedics plans a phase I/II trial in Spinal cord injuries in South Korea (Intrathecal, Injection) in March 2021 (NCT04812431)
26 Mar 2021 Preclinical trials in Spinal cord injuries in South Korea (Intrathecal) prior to March 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com